The Uttarakhand government lifts the ban on five Patanjali medications, saying it was a mistake.

Ayurveda and Unani Licensing Authority of Uttarakhand ordered Divya Pharmacy, which produces Patanjali goods, to halt production of five medications earlier this week due to “misleading ads.” The Uttarakhand government lifted the embargo placed on five medications by Patanjali on November 12, 2022.
The Uttarakhand Ayurveda and Unani Licensing Authority had earlier on Wednesday, November 9th 2022, ordered Divya Pharmacy, the manufacturer of Patanjali goods, to stop producing its five medications, BPgrit, Madhugrit, Thyrogrit, Lipidome, and Eye grit gold tablets. The restriction was implemented in response to claims that these medications are being misrepresented as treatments for excessive cholesterol, goiter, glaucoma, diabetes, blood pressure, and other conditions.
The licensing officer of Uttarakhand Ayurveda and Unani Services sent a letter to the Divya Pharmacy with the following request: “Please kindly take the reference of Directorate’s letter dated 09.11.2022, in which the medications Divya Madhugrit Tablet, Divya Eye grit Gold, Divya Thyrogrit Tablet, Divya BPgrit Tablet, and Divya Lipidome Tablet being manufactured by your firm are According to the requirements in the Drugs and Cosmetics Act, the company is permitted 15 days rather than one week to provide a response in this regard.
After receiving this letter, Divya Pharmacy issued a press release on the subject. “Patanjali Institute is the first in the world to achieve an acceptance for Ayurvedic medicines as research and evidence-based medicine with 30 years of continuous effort and research,” the news release states.
The Honorable Prime Minister is working to eradicate all traces of slavery from the nation in an effort to instill pride in his past. The uninformed, insensitive, and incompetent Ayurveda licensing officer of Uttarakhand is not only ruining the revered tradition of Ayurveda, but also calling into doubt its history and verifiable research, which is a profoundly condemnable behavior. and maliciously disparaged Patanjali.
The statement said, “It is our responsibility to make Ayurveda victorious by challenging them with facts and data from scientific study. Ayurveda is being eradicated by the same department that was tasked with making it the country’s primary form of healthcare and bringing it honor. This regrettable deed is inadmissible to us. The first organization in the world with the most research papers published is Patanjali. It has numerous international level research labs that are accredited by NABL, as well as two hospitals that are NABH approved. Here, more than 500 top-notch scientists are working.
“In these 75 years of independence, no government or other institution has done the job done to take Yoga-Ayurveda to the world,” the press statement continued. The manner of an officer’s activities has caused us great harm. Within the bounds of the law, Patanjali will continue to battle against any conspiracy that attempts to undermine the development of Ayurveda Yoga or join any anti-Sanatan medical mafia conspiracies.
The press release, which was also shared by Acharya Balkrishna, the managing director of Patanjali Ayurved Limited, said, “We are grateful to the government for the way the Uttarakhand government corrected the mistake by taking cognizance of this imprudent act of defaming Ayurveda and this error was corrected as the government took the cognizance.
Following a complaint made in July by ophthalmologist KV Babu of Kerala, the five Patanjali medications were outlawed on November 9th, 2022. On October 11, Babu emailed another grievance to the State Licensing Authority (SLA). Dr. GCN Jangapangi demanded in the interim that the pharmacy immediately and going ahead remove “misleading and offensive marketing” from the media in a letter to the joint director of Divya Pharmacy and drug controller of the state health authority.
The regulator further instructed Patanjali to submit amended formulation sheets and label claims for each of the five formulations for a new round of product certification, citing deceptive advertisements.